Current management of immune thrombocytopenia

Cindy E Neunert

Research output: Contribution to journalReview article

46 Citations (Scopus)

Abstract

Immune thrombocytopenia (ITP) is an autoimmune-mediated condition that results from antibody-mediated destruction of platelets and impaired megakaryocyte platelet production. ITP patients exhibit severe thrombocytopenia and are at risk for significant hemorrhage. Few randomized trials exist to guide management of patients with ITP. Ultimately, each patient requires an individualized treatment plan that takes into consideration the platelet count, bleeding symptoms, health-related quality of life, and medication side effects. This article provides an up-to-date review of management strategies drawing on links between the expanding amounts of clinical trial data and associated biology studies to enhance understanding of the disease heterogeneity with regard to the complex pathogenesis and response to treatment.

Original languageEnglish (US)
Pages (from-to)276-282
Number of pages7
JournalHematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program
Volume2013
DOIs
StatePublished - Jan 1 2013

Fingerprint

Idiopathic Thrombocytopenic Purpura
Blood Platelets
Hemorrhage
Megakaryocytes
Platelet Count
Thrombocytopenia
Quality of Life
Clinical Trials
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Current management of immune thrombocytopenia. / Neunert, Cindy E.

In: Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, Vol. 2013, 01.01.2013, p. 276-282.

Research output: Contribution to journalReview article

@article{fd750d2de24e4d5c8e548436be53b48b,
title = "Current management of immune thrombocytopenia",
abstract = "Immune thrombocytopenia (ITP) is an autoimmune-mediated condition that results from antibody-mediated destruction of platelets and impaired megakaryocyte platelet production. ITP patients exhibit severe thrombocytopenia and are at risk for significant hemorrhage. Few randomized trials exist to guide management of patients with ITP. Ultimately, each patient requires an individualized treatment plan that takes into consideration the platelet count, bleeding symptoms, health-related quality of life, and medication side effects. This article provides an up-to-date review of management strategies drawing on links between the expanding amounts of clinical trial data and associated biology studies to enhance understanding of the disease heterogeneity with regard to the complex pathogenesis and response to treatment.",
author = "Neunert, {Cindy E}",
year = "2013",
month = "1",
day = "1",
doi = "10.1182/asheducation-2013.1.276",
language = "English (US)",
volume = "2013",
pages = "276--282",
journal = "Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program",
issn = "1520-4391",
publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Current management of immune thrombocytopenia

AU - Neunert, Cindy E

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Immune thrombocytopenia (ITP) is an autoimmune-mediated condition that results from antibody-mediated destruction of platelets and impaired megakaryocyte platelet production. ITP patients exhibit severe thrombocytopenia and are at risk for significant hemorrhage. Few randomized trials exist to guide management of patients with ITP. Ultimately, each patient requires an individualized treatment plan that takes into consideration the platelet count, bleeding symptoms, health-related quality of life, and medication side effects. This article provides an up-to-date review of management strategies drawing on links between the expanding amounts of clinical trial data and associated biology studies to enhance understanding of the disease heterogeneity with regard to the complex pathogenesis and response to treatment.

AB - Immune thrombocytopenia (ITP) is an autoimmune-mediated condition that results from antibody-mediated destruction of platelets and impaired megakaryocyte platelet production. ITP patients exhibit severe thrombocytopenia and are at risk for significant hemorrhage. Few randomized trials exist to guide management of patients with ITP. Ultimately, each patient requires an individualized treatment plan that takes into consideration the platelet count, bleeding symptoms, health-related quality of life, and medication side effects. This article provides an up-to-date review of management strategies drawing on links between the expanding amounts of clinical trial data and associated biology studies to enhance understanding of the disease heterogeneity with regard to the complex pathogenesis and response to treatment.

UR - http://www.scopus.com/inward/record.url?scp=84898846064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898846064&partnerID=8YFLogxK

U2 - 10.1182/asheducation-2013.1.276

DO - 10.1182/asheducation-2013.1.276

M3 - Review article

VL - 2013

SP - 276

EP - 282

JO - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

JF - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

SN - 1520-4391

ER -